Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate.

Hwang VJ, Kim J, Rand A, Yang C, Sturdivant S, Hammock B, Bell PD, Guay-Woodford LM, Weiss RH.

Am J Physiol Renal Physiol. 2015 Sep 15;309(6):F492-8. doi: 10.1152/ajprenal.00238.2015. Epub 2015 Jul 8.

2.

Unraveling heterogeneous susceptibility and the evolution of breast cancer using a systems biology approach.

Castellanos-Martín A, Castillo-Lluva S, Sáez-Freire Mdel M, Blanco-Gómez A, Hontecillas-Prieto L, Patino-Alonso C, Galindo-Villardon P, Pérez Del Villar L, Martín-Seisdedos C, Isidoro-Garcia M, Abad-Hernández MM, Cruz-Hernández JJ, Rodríguez-Sánchez CA, González-Sarmiento R, Alonso-López D, De Las Rivas J, García-Cenador B, García-Criado J, Lee DY, Bowen B, Reindl W, Northen T, Mao JH, Pérez-Losada J.

Genome Biol. 2015 Feb 21;16:40. doi: 10.1186/s13059-015-0599-z.

3.

Systems biology of polycystic kidney disease: a critical review.

Menezes LF, Germino GG.

Wiley Interdiscip Rev Syst Biol Med. 2015 Jan-Feb;7(1):39-52. doi: 10.1002/wsbm.1289. Epub 2015 Feb 2. Review.

4.

Microextraction by Packed Sorbent (MEPS) and Solid-Phase Microextraction (SPME) as Sample Preparation Procedures for the Metabolomic Profiling of Urine.

Silva C, Cavaco C, Perestrelo R, Pereira J, Câmara JS.

Metabolites. 2014 Jan 27;4(1):71-97. doi: 10.3390/metabo4010071.

5.

Stability of miRNA in human urine supports its biomarker potential.

Mall C, Rocke DM, Durbin-Johnson B, Weiss RH.

Biomark Med. 2013 Aug;7(4):623-31. doi: 10.2217/bmm.13.44.

6.

Applications of metabolomics for kidney disease research: from biomarkers to therapeutic targets.

Wettersten HI, Weiss RH.

Organogenesis. 2013 Jan-Mar;9(1):11-8. doi: 10.4161/org.24322. Epub 2013 Jan 1. Review.

7.

A Metabolomics Profiling Study in Hand-Foot-and-Mouth Disease and Modulated Pathways of Clinical Intervention Using Liquid Chromatography/Quadrupole Time-of-Flight Mass Spectrometry.

Lu C, Liu X, Ding X, Chen X, Fan H, Liu Y, Xie N, Tan Y, Ko J, Zhang W, Lu A.

Evid Based Complement Alternat Med. 2013;2013:647452. doi: 10.1155/2013/647452. Epub 2013 Feb 19.

8.

Network analysis of a Pkd1-mouse model of autosomal dominant polycystic kidney disease identifies HNF4α as a disease modifier.

Menezes LF, Zhou F, Patterson AD, Piontek KB, Krausz KW, Gonzalez FJ, Germino GG.

PLoS Genet. 2012;8(11):e1003053. doi: 10.1371/journal.pgen.1003053. Epub 2012 Nov 29.

9.

Systematic variations associated with renal disease uncovered by parallel metabolomics of urine and serum.

Gao X, Chen W, Li R, Wang M, Chen C, Zeng R, Deng Y.

BMC Syst Biol. 2012;6 Suppl 1:S14. doi: 10.1186/1752-0509-6-S1-S14. Epub 2012 Jul 16.

10.

Urine metabolomics for kidney cancer detection and biomarker discovery.

Ganti S, Weiss RH.

Urol Oncol. 2011 Sep-Oct;29(5):551-7. doi: 10.1016/j.urolonc.2011.05.013. Review.

11.

Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1).

Wikoff WR, Nagle MA, Kouznetsova VL, Tsigelny IF, Nigam SK.

J Proteome Res. 2011 Jun 3;10(6):2842-51. doi: 10.1021/pr200093w. Epub 2011 Apr 22.

Supplemental Content

Support Center